Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMSU06X)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Hemicholinium; 16478-59-4; 2,2'-(Biphenyl)-4,4'-diylbis(2-hydroxy-4,4-dimethylmorpholinium); 2,2'-(4,4'-Biphenylene)bis(2-hydroxy-4,4-dimethylmorpholinium); 2-[4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl]-4,4-dimethylmorpholin-4-ium-2-ol; Morpholinium, 2,2'-(4,4'-biphenylene)bis(2-hydroxy-4,4-dimethyl-; Prestwick3_000393; Prestwick0_000393; Prestwick1_000393; Prestwick2_000393; AC1L1G9B; Lopac0_000578; BSPBio_000605; SPBio_002526; CHEMBL268697; BPBio1_000667; GTPL4494; SCHEMBL12638596; 8-amino-5'-deoxy-5'-chloroguanosine
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||
|
||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||
